|
ESAs: whatever happened to evidence-based medicine?
Pennsylvania Hospital, Philadelphia, PA
With new data, new FDA rulings, and news across the media on rebates—some call them kickbacks—paid to oncologists and other specialists, erythropoiesis-stimulating agents are at the white hot center of a debate in medicine. Are these drugs overprescribed by physicians eager to collect cash from pharma? Or are they quality-of-life-saving medications doled out judiciously and appropriately? In a series of articles found in the next few pages, as well as two Having Your Say opinion pieces beginning on page 367, we sort through the controversy.
| Commun Oncol 2007;4:389–394 | full text |  118 kb |